Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

217
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
217
Genetic Screens02:46

Genetic Screens

5.6K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.6K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

399
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
399
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

155
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
155

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrafast Self-Assembly of Zeolitic Imidazolate Framework-8 Enables Antibody Orientation for Ultrasensitive Lateral Flow Immunoassays.

ACS nano·2026
Same author

Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer.

ACS applied bio materials·2026
Same author

Programmable DNA hydrogels for dual-mode PD-L1 suppression via polyvalent LYTAC mimics and transcriptional silencing.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

On-demand formation of ultrathin liquid metal hydrogel tattoos for conformal and low-impedance bioelectronics.

Science advances·2026
Same author

Side-Port Puncture Needle-Assisted, Multistep Vacuum-Driven Microfluidic Chip for Multiplexed Molecular Analysis.

Analytical chemistry·2026
Same author

Gold Nanoparticles Regulate Gut Microbiota and Immune Responses for Overcoming Iron Supplementation Side Effects in Anemia Therapy.

ACS nano·2026

Related Experiment Video

Updated: Jan 25, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.1K

Cell-Based Assays on Microfluidics for Drug Screening.

Xiaoyan Liu1,2,3, Wenfu Zheng1,3, Xingyu Jiang1,4,3

  • 1Beijing Engineering Research Center for BioNanotechnology and CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience , National Center for NanoScience and Technology , No. 11 Zhongguancun Beiyitiao , Beijing 100190 , P. R. China.

ACS Sensors
|May 11, 2019
PubMed
Summary

Microfluidic devices offer a sensitive, high-throughput, and ethical alternative for drug screening. These advanced platforms mimic in vivo conditions, improving in vitro models for drug discovery.

Keywords:
biomimeticscell assaydrug screeninghigh-throughputmicrofluidics

More Related Videos

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K

Related Experiment Videos

Last Updated: Jan 25, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

25.1K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.8K

Area of Science:

  • Biomedical Engineering
  • Drug Discovery
  • Microfluidics

Background:

  • Conventional drug screening methods (Petri dishes, animal models) face limitations including ethical concerns and lack of in vivo relevance.
  • Microfluidic devices present advantages such as miniaturization, ease of use, high sensitivity, and high throughput for bioassays.
  • Three-dimensional (3D) microfluidic chips can better replicate in vivo biochemical and biophysical conditions, creating more accurate in vitro models.

Purpose of the Study:

  • This perspective focuses on cell-based microfluidic assays for drug screening.
  • It aims to address current challenges in the field of microfluidic drug screening.
  • The study discusses the future prospects of microfluidics-based drug discovery technologies.

Main Methods:

  • Review and analysis of current microfluidic technologies for cell-based drug screening.
  • Identification of challenges and limitations in implementing microfluidic assays.
  • Exploration of potential solutions and future directions for microfluidic drug discovery.

Main Results:

  • Microfluidic platforms offer significant advantages over traditional methods for drug screening.
  • 3D microfluidic chips provide more physiologically relevant in vitro models.
  • Ethical concerns associated with animal testing can be mitigated using microfluidics.

Conclusions:

  • Microfluidics represents a promising platform for advancing drug screening and discovery.
  • Overcoming current technical hurdles will further enhance the utility of microfluidic devices.
  • The future of drug discovery is significantly influenced by the development of microfluidics-based technologies.